A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort pMDI [budesonide/formoterol] 40/2.25 microg twice daily compared with 1 inhalation Symbicort Turbuhaler [budesonide/formoterol] 80/4.5 microg twice daily and 1 inhalation Pulmicort Turbuhaler [budesonide] 100 microg twice daily.
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ESTHER
- Sponsors AstraZeneca
- 14 Aug 2012 Actual end date changed from 1 Feb 2008 to 1 Apr 2008 as reported by ClinicalTrials.gov.
- 15 Mar 2012 Actual end date (1 Feb 2008) added as reported by EudraCT.
- 15 Apr 2008 Status change from in progress to completed, according to clinicaltrials.gov.